Lineage Cell Therapeutics (LCTX) Other Accumulated Expenses (2011 - 2023)

Lineage Cell Therapeutics' Other Accumulated Expenses history runs 13 years deep, the most recent figure standing at $1000.0 for Q2 2023.

• On a quarterly basis, Other Accumulated Expenses fell 90.0% year-over-year to $1000.0 in Q2 2023; TTM through Jun 2023 was $1000.0, a 90.0% decrease from a year earlier, with the FY2021 full-year figure at $178000.0, up 1877.78% from the prior year.
• Other Accumulated Expenses fell to $1000.0 in Q2 2023 per LCTX's latest filing, from $37000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $492000.0 in Q2 2021 and bottomed at $1000.0 in Q2 2023.
• The 5-year median for Other Accumulated Expenses is $31000.0 (2022), against an average of $78187.5.
• Across the five-year window, Other Accumulated Expenses surged 1877.78% in 2021 and tumbled 97.97% in 2022, its largest moves.
• Year by year, Other Accumulated Expenses stood at $4000.0 in 2019, then jumped by 125.0% to $9000.0 in 2020, then jumped by 1877.78% to $178000.0 in 2021, then slumped by 85.96% to $25000.0 in 2022, then tumbled by 96.0% to $1000.0 in 2023.
• Per Business Quant, the three latest LCTX Other Accumulated Expenses figures stand at $1000.0 (Q2 2023), $37000.0 (Q1 2023), and $25000.0 (Q3 2022).